Skip to main content

RxSight, Inc. Educational and Product Announcements for AAO 2023

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

ALISO VIEJO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- November 2, 2023 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced educational opportunities and product updates at the American Academy of Ophthalmology (AAO) Annual Meeting on November 3 – 6 in San Francisco. These include three scientific poster presentations (PO005, PO457, PO050) and 15 booth presentations (booth #229). At these events, leading U.S.-based ophthalmologists are slated to discuss diverse topics, including maximizing clinical results using the Light Adjustable Lens™ (LAL®) across a broad range of patient profiles, integration of the adjustable lens workflow, and real-life case studies showing the impact of high-quality, customized LAL vision. For the full program of events taking place at AAO 2023, click here.

One of these presentations (by Steven Slade, MD, of Houston-based Slade & Baker Vision on November 4 at 10:30 a.m.) will report clinical results using the LAL+, a new addition to the LAL family that will become available in the first quarter of 2024. The LAL+ has a built-in optical feature that is designed to further extend the depth of focus before light treatments, while preserving the high-quality vision of the LAL already familiar to customers and patients.

RxSight’s reconfigured Light Delivery Device (LDD™) will also be on display during AAO. While providing the same functionality and outcomes as the standard LDD, this compact model has a smaller footprint to address global practice space constraints.

About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Company Contact:
Shelley B. Thunen
Chief Financial Officer
sthunen@rxsight.com

Investor Relations Contact:
ir@rxsight.com


Primary Logo

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  263.99
+8.91 (3.49%)
AAPL  271.06
-2.37 (-0.87%)
AMD  347.81
+42.48 (13.91%)
BAC  52.05
-0.42 (-0.80%)
GOOG  342.32
+4.57 (1.35%)
META  675.03
+15.88 (2.41%)
MSFT  424.62
+8.87 (2.13%)
NVDA  208.27
+8.63 (4.32%)
ORCL  173.28
-3.00 (-1.70%)
TSLA  376.30
+2.58 (0.69%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.